Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Tumors

Interventions

DRUG: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod
DRUG: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo

Sponsor

Nina Bhardwaj

Collaborators

[object Object]